Medy-Tox Incorporation operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Medy-Tox Incorporation with three other
companies in this sector in South Korea:
Cell Biotech Co ., Limited.
sales of 49.50 billion Korean Won [US$44.01 million]
of which 84%
was Finished Products),
Komipharm International Company Limited
(36.41 billion Korean Won [US$32.36 million]
of which 100%
was Animal Pharmaceutical), and
(65.07 billion Korean Won [US$57.84 million]
During the year ended December of 2015, sales at
Medy-Tox Incorporation were 88.51 billion Korean Won (US$78.68 million).
increase of 16.6%
versus 2014, when the company's sales were 75.89 billion Korean Won.
This was the fifth consecutive year of sales increases at Medy-Tox Incorporation
(and since 2010, sales have increased a total of 320%).